CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105
CEO.CA, a leading investor social network for venture stocks, has released an exclusive interview with John Yu, CEO & Chairman of Kairos Pharma (NYSE: KAPA), discussing their cancer treatment ENV105. The interview, part of CEO.CA's 'Inside the Boardroom' series, focuses on the company's recent funding and its impact on research acceleration.
The interview is available on CEO.CA's platform and YouTube channel, which serves millions of visitors annually as one of Canada's most popular financial websites. The platform, founded in 2012 and now a subsidiary of EarthLabs, Inc., offers investors worldwide a space to connect, share knowledge, and access information about stocks, commodities, and emerging companies.
CEO.CA, una rete sociale per investitori leader nel settore delle azioni di venture, ha pubblicato un'intervista esclusiva con John Yu, CEO e Presidente di Kairos Pharma (NYSE: KAPA), in cui si discute del loro trattamento per il cancro ENV105. L'intervista, parte della serie 'Inside the Boardroom' di CEO.CA, si concentra sul recente finanziamento dell'azienda e sul suo impatto sull'accelerazione della ricerca.
L'intervista è disponibile sulla piattaforma di CEO.CA e sul canale YouTube, che serve milioni di visitatori ogni anno come uno dei siti finanziari più popolari del Canada. La piattaforma, fondata nel 2012 e ora una filiale di EarthLabs, Inc., offre agli investitori di tutto il mondo uno spazio per connettersi, condividere conoscenze e accedere a informazioni su azioni, materie prime e aziende emergenti.
CEO.CA, una red social de inversores líder en acciones de riesgo, ha publicado una entrevista exclusiva con John Yu, CEO y Presidente de Kairos Pharma (NYSE: KAPA), donde se discute su tratamiento para el cáncer ENV105. La entrevista, parte de la serie 'Inside the Boardroom' de CEO.CA, se centra en la reciente financiación de la empresa y su impacto en la aceleración de la investigación.
La entrevista está disponible en la plataforma de CEO.CA y en su canal de YouTube, que recibe millones de visitantes anualmente como uno de los sitios financieros más populares de Canadá. La plataforma, fundada en 2012 y ahora una subsidiaria de EarthLabs, Inc., ofrece a los inversores de todo el mundo un espacio para conectarse, compartir conocimientos y acceder a información sobre acciones, materias primas y empresas emergentes.
CEO.CA는 벤처 주식 투자자들을 위한 선도적인 소셜 네트워크로, John Yu CEO 겸 회장과의 독점 인터뷰를 공개했습니다. 인터뷰에서는 Kairos Pharma (NYSE: KAPA)의 암 치료제 ENV105에 대해 논의합니다. 이 인터뷰는 CEO.CA의 'Inside the Boardroom' 시리즈의 일환으로, 회사의 최근 자금 조달과 연구 가속화에 미치는 영향에 중점을 두고 있습니다.
인터뷰는 CEO.CA 플랫폼과 유튜브 채널에서 확인할 수 있으며, 캐나다에서 가장 인기 있는 금융 웹사이트 중 하나로 매년 수백만 명의 방문자를 제공합니다. 2012년에 설립된 이 플랫폼은 현재 EarthLabs, Inc.의 자회사로, 전 세계 투자자들에게 연결하고 지식을 공유하며 주식, 원자재 및 신생 기업에 대한 정보를 액세스할 수 있는 공간을 제공합니다.
CEO.CA, un réseau social d'investisseurs leader pour les actions de capital-risque, a publié une interview exclusive avec John Yu, PDG et Président de Kairos Pharma (NYSE: KAPA), discutant de leur traitement du cancer ENV105. L'interview, faisant partie de la série 'Inside the Boardroom' de CEO.CA, se concentre sur le récent financement de l'entreprise et son impact sur l'accélération de la recherche.
L'interview est disponible sur la plateforme de CEO.CA et sur leur chaîne YouTube, qui attire des millions de visiteurs chaque année en tant que l'un des sites financiers les plus populaires du Canada. La plateforme, fondée en 2012 et maintenant une filiale d'EarthLabs, Inc., offre aux investisseurs du monde entier un espace pour se connecter, partager des connaissances et accéder à des informations sur les actions, les matières premières et les entreprises émergentes.
CEO.CA, ein führendes soziales Netzwerk für Investoren im Bereich Risikokapital, hat ein exklusives Interview mit John Yu, CEO und Vorsitzender von Kairos Pharma (NYSE: KAPA), veröffentlicht, in dem es um ihre Krebsbehandlung ENV105 geht. Das Interview, Teil der Serie 'Inside the Boardroom' von CEO.CA, konzentriert sich auf die kürzliche Finanzierung des Unternehmens und deren Auswirkungen auf die Beschleunigung der Forschung.
Das Interview ist auf der Plattform von CEO.CA und dem YouTube-Kanal verfügbar, der jährlich Millionen von Besuchern anzieht und zu den beliebtesten Finanzwebsites Kanadas zählt. Die 2012 gegründete Plattform ist jetzt eine Tochtergesellschaft von EarthLabs, Inc. und bietet Investoren weltweit einen Raum, um sich zu vernetzen, Wissen auszutauschen und Informationen über Aktien, Rohstoffe und aufstrebende Unternehmen zu erhalten.
- None.
- None.
Toronto, Ontario--(Newsfile Corp. - March 28, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.
Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality. Millions of people visit CEO.CA each year to connect with investors from around the world, share knowledge and view impactful stories about stocks, commodities, and emerging companies.
Meet the Executives Shaping the Pharmaceutical Landscape
'Inside the Boardroom' is more than just an interview series - it's a chance to gain firsthand knowledge from industry leaders, understanding their vision, challenges, and strategy.
We caught up with John Yu, CEO & Chairman of Kairos Pharma (NYSE: KAPA), to discuss their groundbreaking cancer treatment ENV105 and how recent funding is accelerating their research.
Kairos Pharma
NYSE: KAPA
Cannot view this video? Visit:
https://www.youtube.com/watch?v=jui7OZ88BJQ
Tune into 'Inside the Boardroom' each week and be part of the conversation that's shaping the business landscape. Visit CEO.CA or our YouTube page for hundreds more executive interviews from CEO.CA here.
Interested in showcasing your company on 'Inside the Boardroom'? Get in touch with our team at sales@ceo.ca for further details and opportunities.
About CEO.CA
The leading community for investors & traders in junior resource & venture stocks. CEO.CA is one of the most popular free financial websites and apps in Canada and for small-cap investors globally -- with industry leading audience engagement and mobile functionality. Since 2012, CEO.CA has brought millions of investors together from over 164 countries to discuss their portfolio holdings and find new investment opportunities. Download our App on iOS or Android marketplace or visit us today at CEO.CA to set up your free account.
CEO.CA is a wholly owned subsidiary of EarthLabs, Inc.
For further information please contact:
CEO.CA
Email: hello@ceo.ca
Website: CEO.CA
Neither the TSX Venture Exchange ("TSXV"), OTC Best Market "(OTCQX") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
The information regarding any issuer contained or referred to in any interviews conducted by CEO.CA has been furnished by such issuer directly, and neither CEO.CA nor any of its affiliates or principals assumes any responsibility for the accuracy or completeness of such information or for any failure by an issuer to ensure disclosure of events or facts which may affect the significance or accuracy of any such information.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release may include, but is not limited to, the objectives, goals, future plans, statements regarding exploration results and exploration and/or development plans of companies featured on the CEO.CA platform. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects, currency risk and the other risks involved in the applicable exploration and development industry, and those risks set out in the public documents of such companies filed on SEDAR or elsewhere from time to time. Undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. CEO.CA disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246410
FAQ
What is Kairos Pharma's (KAPA) new cancer treatment ENV105?
When did Kairos Pharma (KAPA) receive their recent funding for ENV105 research?
Where can investors watch the Kairos Pharma (KAPA) ENV105 interview?
What was discussed in the Inside the Boardroom interview with Kairos Pharma (KAPA)?
